Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
Company nameGrail Inc
IPO dateJun 12, 2024
Founded at2020
CEOMr. Robert (Bob) Ragusa
Number of employees1000
Security typeOrdinary Share
Fiscal year-endJun 12
Address1525 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94025
Phone18336942553
Websitehttps://grail.com/
Ticker SymbolGRAL
IPO dateJun 12, 2024
Founded at2020
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data